Cefiderocol for the Treatment of Adult and Pediatric Patients with Cystic Fibrosis and Achromobacter xylosoxidans Infections

Alby K.; Alexander J.; Bartelt L.A.; Brown D.E.; Brownstein M.J.; Burch A.-K.; Carr A.L.; Cheema F.; Daniels R.; Gainey A.B.; Jones M.B.; Lachiewicz A.M.; Linder K.E.; Longworth S.; Miller M.B.; Shields R.K.; Tompkins K.M.; Van Duin D.; Warner N.C.

Cefiderocol for the Treatment of Adult and Pediatric Patients with Cystic Fibrosis and Achromobacter xylosoxidans Infections

Authors: Alby K.
Alexander J.
Bartelt L.A.
Brown D.E.
Brownstein M.J.
Burch A.-K.
Carr A.L.
Cheema F.
Daniels R.
Gainey A.B.
Jones M.B.
Lachiewicz A.M.
Linder K.E.
Longworth S.
Miller M.B.
Shields R.K.
Tompkins K.M.
Van Duin D.
Warner N.C.
Publication date: 1 January 2021
Publisher: Oxford University Press
Doi

Abstract

Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Carolina Digital Repository

cdr.lib.unc.edu:b8516044n

Last time updated on 23/01/2024